Blastic Plasmacytoid Dendritic Cell Neoplasm: The European Perspective.
Fiche publication
Date publication
juin 2020
Journal
Hematology/oncology clinics of North America
Lien Pubmed
Résumé
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) has to be considered an orphan tumoral disease. BPDCN is a good model concerning the structuring and the organization of a concerted medical program on a nation-based, transnational, or international level. In 2019 in France the diagnosis process for BPDCN was clearly established. Two prospective clinical trials are ongoing. Because of the difficulties in diagnostic procedures and the rarity of the disease it is important that European countries collaborate to build a real European network to ensure the best and equitable medical care to all BPDCN patients.
Mots clés
Allogeneic transplantation, BPDCN, Europe, International cooperation, Network, Orphan disease, Tagraxofusp
Référence
Hematol. Oncol. Clin. North Am.. 2020 Jun;34(3):613-620